Jér?me Laloze, Alexis Desmoulière
1Faculties of Medicine and Pharmacy, Myelin Maintenance and Peripheral Neuropathies (EA 6309), University of Limoges, Limoges F-87000, France.
2Department of Maxillo-Facial and Reconstructive Surgery and Stomatology, University Hospital Dupuytren, Limoges F-87000, France.
The wound healing process is complex and, despite many advances in both fundamental research and plastic surgery, the mechanisms underlying tissue repair remain poorly understood.
After surgery or trauma, the plastic surgeon needs to use all the means at his or her disposal to both obtain a stable scar and achieve the most aesthetic result. However, before this can be achieved, there is a long and sometimes difficult phase, lasting up to 18-24 months. Moreover, the surgeon will sometimes have to deal with complications related to either poor or excessive (defective or pathological) scarring. These complications, which are both physiological and psychological, particularly in aesthetic plastic surgery, are difficult to treat since there is at present no consensus, and they thus continue to represent a significant public health issue. Therefore, it is important to understand all of the closely interwoven aspects of healing, including structural and surgical aspects, for both prevention and revision of scarring.
Prevention of scarring involves good surgical technique, adaptation to the individual patient and the use of creams, compression and physiotherapy. Revision involves a thorough knowledge of the different stages of healing and the specific dressings related to these stages. In any case, close patient support is still necessary.
With this special issue on “scar tissue prevention and revision”, we aim to summarize the state of the art of both translational and clinical research and present current trends and future prospects for the management of wound healing.
We are fortunate that for this special issue renowned authors have agreed to share their experiences on the subject of pathological scarring.
Scar repair in adult skin has been studied in depth over many years. The healing process is very complex, since many cells and trophic factors are involved, which interact with each other. Healing also involves a well-defined sequence of phases[1], of which inflammation is the first, and possibly most important, phase when considering future pathological scar formation.
For this reason, we are greatly interested in the review of the literature by Wilgus[2], which reminds us of the prominent role of inflammation in the scarring process. Several reviews have already highlighted a link between the occurrence of pathological scarring and excessive inflammation[3]. Indeed, in scar tissue, higher concentrations of mediators such as interleukins (IL)-6 and IL-8, which are both pro-inflammatory cytokines[4], and increased numbers of pro-inflammatory cells (mast cells and macrophages)[5]are present. These molecular and cellular findings are of obvious clinical interest. Thus, local or systemic therapies that can reduce inflammation are used in this goal. Corticosteroids, for example, have long been used to treat hypertrophic scars or keloid scars by intra-lesional injections[6,7], with their value having been demonstrated in several studies. Other treatments such as nonsteroidal anti-inflammatory drugs[8,9], toll like receptor-4 inhibitors[10], CXCR4 antagonists[11], pirfenidone[12], epigallocatechin-3-gallate[13]or fibromodulin[14]are also currently being studied. Even though results on these latter therapies are conflicting, Wilgus outlined the treatment arsenal available to the clinician who is sometimes lost when faced with the distress caused by these scars.
Wilgus also discussed two phenomena that are well known by surgeons and nurses when dealing with scars. It is important to reduce the tension in the scar[15]and maintain a moist environment[16]in order to reduce scar inflammation and thus reduce the risk of scar tissue formation. For example, focal adhesion kinase (FAK) signaling pathways, which control mechanical signaling in fibroblasts, are linked to an increased inflammatory response[17]. Future treatments could be used to target and control these FAK signaling pathways. Very recently, Fuet al.[18]published an interesting review on the phenomenon of mechanotransduction in wound healing, outlining the principles and pathways involved. In it, they reviewed the numerous clinical tools that are based on this pathway and can be used to manage the complex or large wounds that would definitely lead to major scar tissue. Clinicians can easily identify these tools: the expanders used in the aftermath of burns or giant nevi[19], the External Vacuum Expander (EVE?) or BRAVA? system in breast augmentation[20], negative pressure therapy for complex and deep wounds[21], Zplasty[22],etc. Fuet al.[18]thus provided a description of “mechanotransduction to mechanotherapy”.
Scar tissue can occur after traumatic injuries (burns,etc.) as well as after surgery[23]. However, Mirastschijskiet al.[24]pointed out that not all regions are equal in terms of healing. Indeed, the skin of the genital region, thanks to the embryological origins of its fibroblasts and its hormonal environment, has very specific healing properties. Pathological scars are rare in this body region.
Conversely, after a burn, the frequency of pathological scars such as hypertrophic scars, keloids or retractile scars can be as high as 70%[24,25][Figure 1]. Scar tissue shows different properties to normal skin in terms of reduced tensile strength, reduced laxity and being more rigid to palpation. It can thus cause physical suffering (pruritus, pain, erythema,etc.) as well as psychological suffering[26,27]. It is therefore essential to optimize their management. The paper by Wonget al.[28]presents the current therapeutic possibilities for the prevention of these scars (compression therapy, silicone plat and massage therapy) and their treatment (surgical revision, laser therapy, corticosteroids,etc.). Interestingly, they also provided an overview of new approaches for the treatment of hypertrophic scars after burns. These include, for example, therapies regulating transforming growth factor-β, such as Juvista[29]or Juvidex[30]; Prevascar (a recombinant human IL-10 product), which can decrease the action of IL-6 and IL-8[30,31]; mesenchymal stem cells or epithelial cells[32]; and finally new polymer-stress shielding devices[15,33]that act via reducing the mechanical stress in scar tissue. This last point is also addressed by the article of Lemperle[34]on the importance of tensional forces in the skin in surgical scar placement.
Figure 1. Retractile scar after burn injuries during childhood, involving the elbow, wrist and fingers.
Indeed, regarding the phenomena of mechanical tension, another means exists that has been well known by plastic surgeons for more than a century (since 1861)[35]to reduce the risk of hypertrophic scarring after surgery, which is to position (as much as possible) future surgical scars along the lines of least skin tension, i.e., according to Langer’s lines. Lemperle[34]emphasized the importance of these planned incisions in a richly illustrated and exhaustive article, which covers each part of the body separately. Thus, care must be taken to observe the lines of least skin tension, which are themselves perpendicular to the orientation of stretch marks[36].
Finally, a risk factor that is comparatively unknown to the scientific community, and which could also contribute to causing pathological scars, is the level of stress. Yanget al.[37]studied this phenomenon and sought to understand how emotion could play a role in the appearance of such scars or encourage their recurrence (which remains very high in keloid scars, ranging 9%-100%). Indeed, they identified three possible pathways involved: stress hormones (norepinephrine and epinephrine) increase the level of IL-6 by activating-adrenergic receptors, increase the growth and proliferation of fibroblasts in scar tissue by activating-adrenergic receptors, and dysregulate the immune system by promoting an inflammatory environment.In this special issue, we trust that both clinicians and researchers will find accurate and up to date answers regarding the prevention of scar tissue and scar revision.
DECLARATIONS
Authors’ contributions
Writing and drafting of the manuscript, providing of the illustration: Laloze J
Advice and intellectual support, correction and proofreading of the manuscript: Desmoulière A
Available of data and materials
Not applicable.
Financial support and sponsorship
None.
Conflicts of interest
Both authors declared that there are no conflicts of interest.
Ethical approval and consent to participate
All patients sign a consent form at the time of admission that they are informed that any photos may be used for scientific purposes and publications.
Consent for publications
Not applicable.
Copyright
? The author(s) 2021.
Plastic and Aesthetic Research2021年5期